The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Business
  • Construction
  • Entertainment
  • Marketing
  • Health

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love
  • PropAccount.com Adds Prediction Markets to Its Multi-Asset Prop Firm Platform
  • Detained at 95: South Korea's Prosecution of a Religious Leader Draws International Alarm
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • New School Announces Student Enrollment
  • Able Rooter Expands Services to Offer Premium Water Heater Installation Across St. Louis
  • Director Sean McNamara Reunites with Award-Winning Cinematographer Shawn Seifert for Upcoming Feature Home
  • J. Kenton Pierce Wins Prometheus Award for Best Novel
  • Ezra Wohlgelernter Named as a 2026 Philadelphia Power Broker by City & State PA

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Florida Law Advisers, P.A. Named Best Divorce Firm of 2026 by Expert Law Attorneys
  • Sounds of LA County: 27 Parks.108 Concerts. One County
  • Only One Flight Stands Between Los Angeles Youth Leaders and a Life-Saving Mission in South Africa
  • Blueshirt Media Joins the Dazos Partner Program, Expanding HIPAA-Compliant AI Admissions Support for Behavioral Health Organizations
  • Stigma Across Borders: Concerns Grow Over Discrimination Against Shincheonji Members Abroad
  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • World Cup Crowds Are a Stress Test for America's Restrooms
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • How Sacramento Families Are Using Private Autopsies to Protect Inheritances, Resolve Insurance Claims, and Find Closure
  • Los Angeles' Best Food: Food Journal Magazine Examines the Trends Shaping the City's Dining Scene
  • Landmark Construction Expands Glass, Glazing, and Commercial Remodeling Services Across Los Angeles County and Surrounding Areas
  • Imagen Golf Announces Strategic Partnership with The Back Nine of Yardley to Deliver World-Class Indoor Golf Instruction
  • Jazzin' On Ridge Returns for Its 6th Annual Celebration of Music, Culture, and Community
  • ENTOUCH Named Top 100 Inspiring Workplaces in North America for Third Consecutive Year
  • Rebecca L. Francis Receives Pennsylvania's Most Influential Leaders Award
  • Pulse Wave is where moments become movements
  • Michigan's Plane Crash Data Points Away from Big Airports
  • 2iG Solutions Launches MGA Insight, Bringing AI-Powered Business Intelligence to Managing General Agents
  • A Better Way to Find a Real Estate Agent Is Coming Soon
  • Talentica Software Earns a Place Among India's Top 100 Great Mid-size Workplaces 2026

Popular on PennZone

  • ReviewsAlly Launches Evidence-Based Review Platform for VPNs, Business Software, and Online Services
  • STO Foundation Launching June 29, 2026 to Advance the Global Tokenization Industry
  • Top 5 Most Reliable Used Vans in the UK in 2026
  • Allstream Energy Partners to Host 6th Executive Networking After 2026 Energy Projects Conference
  • Turnstone Creative's Ashley Russo Serves as Emcee for United Way's 2026 NERC and Women's Summit
  • Justice Advisory Group Expands Federal Sentencing, Prison Preparation and Reentry Support Services
  • Leimert Juneteenth Community Celebration Set for Friday, June 19, in Leimert Park Village
  • Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
  • Freedomtech Solutions Launches the World's First Pre‑Installed Agentic AI Server — Instant, Sovereign, Infrastructure‑Native Intelligence
  • Compton to host first Juneteenth celebration with We Are Us Festival

Similar on PennZone

  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us